Formerly called arrhythmogenic right ventricular dysplasia.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is caused by fibro-fatty replacement of RV myocytes due to apoptosis, inflammation (definite causes for either mechanism are as yet unknown) or a genetic cause. It usually presents with symptomatic arrhythmias or sudden death.
Diagnosing ARVC is difficult due to nonspecific disease features and phenotypic manifestations. Echocardiographic features include increased RV dimensions, RV regional wall motion abnormalities and dysfunction. RV angiography has been considered the gold standard for diagnosis, but MRI has better sensitivity and specificity.
In ARVC, severe RV dysfunction is treated with standard heart failure medications and cardiac transplantation is considered if treatment is refractory. Beta-blockers are used in asymptomatic patients and inplantable cardioverter defibrillator (ICD) is mandated in high-risk patients.
The precise aetiology remains unknown.
- ARVC is uncommon, affecting around 1 in 2,000 adults.It is more common in people from northern Italy and Greece.
- ARVC most often presents in adolescence and early adulthood.
- It is more common in males.
- It is familial in 30-50%of cases.
- It is transmitted in autosomal dominant (more common) and autosomal recessive forms and involves mutations in desmosomal and extra-desmosomal genes.
- ARVC is recognised as a leading cause of sudden cardiac death (SCD) in young adults under 35 years of age and may even account for up to 10% of cardiovascular deaths in the under-65 age group.
ARVC generally presents in men aged 15-35 with palpitations, presyncope or syncope. Sudden death can be the first presentation. Patients who survive into their fourth and fifth decades can present with biventricular or right heart failure (without pulmonary hypertension).
Atrial arrhythmias are common in ARVC and present at a younger age than in the general population. They are associated with male gender, increasing age, and left atrial enlargement. Atrial arrhythmias are clinically important, as they are associated with inappropriate ICD shocks and increased risk of both death and heart failure.
The features of ARVC depend on the phase of disease progression:
- Concealed phase:
- Subtle RV changes, with or without minor ventricular arrhythmias.
- These may occasionally be the first manifestation as SCD, usually in the young engaged in competitive sports or intense exercise.
- Overt electrical disorder:
- Symptomatic RV arrhythmias associated with functional and structural abnormalities of the right ventricle.
- Usually presents with palpitations or syncope.
- Arrhythmias and SCD are common. Previously undiagnosed ARVC accounts for about 20% of SCDs.
- RV failure:
- Extension of disease to the whole of the right ventricle causes dysfunction.
- Biventricular pump failure - end stage:
- Left ventricular involvement leads to heart failure and may mimic dilated cardiomyopathy.
NB: around half of patients will have a normal physical examination.
The following investigations are usually undertaken:
- Assessment of cardiac function and disease aetiology:
- Blood tests, including FBC, ESR/CRP, renal function and electrolytes, and LFTs; cardiac enzymes may be appropriate, depending on presentation.
- ECG - the most common findings are ventricular arrhythmias with left bundle branch block (LBBB) morphology.
- Cardiac catheterisation.
- Cardiac MRI scan - RV enlargement, fatty infiltration, fibrosis and wall motion abnormalities.
- RV angiography is considered a very useful test to diagnose classic forms of ARVC and to evaluate RV function.
- Heart biopsy in some cases.
- Genetic assessment.
- For patients with well tolerated or non life-threatening ventricular arrhythmias, beta-blockers, such as sotalol, or amiodarone with/without beta-blocker, are the most effective drugs with a relatively low proarrhythmic risk.
- For sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), serial therapeutic drug trials are used, using programmed ventricular stimulation to assess effectiveness.
- Patients who remain inducible of arrhythmias usually require an ICD, except for rare cases with localised disease where catheter ablation may be an option.
- Radio-frequency ablation results in a significant reduction in the burden of VT in patients with ARVC.
- In patients who are not inducible, and present in cardiac arrest or syncope, an automatic ICD is the first option.
- ICDs are the most effective intervention in prevention of arrhythmic sudden death.
- Cardiac and non-cardiac mortality rates after ICD implantation in patients with ARVC are low.
- Treat associated heart failure.
- Heart transplantation may need to be considered in refractory cases in end-stage failure.
- ARVC tends to be progressive with deterioration of RV function.
- The left ventricle may become involved with progression of the degenerative process.
- Although AVRC is a progressive disease, the individual disease course can vary considerably.
- The mortality rate is currently estimated to be around 1-3% per year.
Did you find this information useful?
- Saguner AM, Brunckhorst C, Duru F; Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease. World J Cardiol. 2014 Apr 26 6(4):154-174.
- Al-Sabeq B, Krahn AD, Conacher S, et al; Arrhythmogenic right ventricular cardiomyopathy with recessive inheritance related to a new homozygous desmocollin-2 mutation. Can J Cardiol. 2014 Jun 30(6):696.e1-3. doi: 10.1016/j.cjca.2014.01.014. Epub 2014 Jan 23.
- Camm CF, James CA, Tichnell C, et al; Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013 Nov 10(11):1661-8. doi: 10.1016/j.hrthm.2013.08.032. Epub 2013 Aug 28.
- Philips B, Madhavan S, James C, et al; Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012 Jun 1 5(3):499-505. doi: 10.1161/CIRCEP.111.968677. Epub 2012 Apr 6.
- Arrhythmia - implantable cardioverter defibrillators; NICE Technology Appraisal, January 2006
- Dohadwala M, Link MS; Implantable Defibrillators in Long QT Syndrome, Brugada Syndrome, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular Cardiomyopathy. Cardiol Clin. 2014 May 32(2):305-318. doi: 10.1016/j.ccl.2013.11.003. Epub 2014 Jan 23.
- Schinkel AF; Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol. 2013 Jun 6(3):562-8. doi: 10.1161/CIRCEP.113.000392. Epub 2013 May 14.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.